Publications by authors named "Vicky Hsu"

Claim this Profile
F
FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation.
Gulsum E Pamuk, Edwin C Y Chow, Alexei C Ionan, Haiyan Chen, Shwu-Luan Lee, Vicky Hsu

Clin Cancer Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.
Elaine Chang, Chana Weinstock, Lijun Zhang, Rosane Charlab, Sarah E Dorff, Vicky Hsu

Clin Cancer Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
Kelly J Norsworthy, Lola Luo, Vicky Hsu, Ramadevi Gudi, Sarah E Dorff

Clin Cancer Res· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches.
Yingying Guo, Xiaoyan Chu, Neil J Parrott, Kim L R Brouwer, Vicky Hsu

Clin Pharmacol Ther· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Performance of Physiologically-Based Pharmacokinetic Models in Predicting Drug-Drug Interactions Involving Enzyme Modulation.
Chia-Hsiang Hsueh, Vicky Hsu, Yuzhuo Pan, Ping Zhao

Clin Pharmacokinet· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives.
Yuzhuo Pan, Vicky Hsu, Manuela Grimstein, Lei Zhang, Vikram Arya

J Clin Pharmacol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA.
Christian Wagner, Yuzhuo Pan, Vicky Hsu, Vikram Sinha, Ping Zhao

Clin Pharmacokinet· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration.
Christian Wagner, Yuzhuo Pan, Vicky Hsu, Joseph A Grillo, Lei Zhang

Clin Pharmacokinet· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations.
Vicky Hsu, Manuela de L T Vieira, Ping Zhao, Lei Zhang, Jenny Huimin Zheng

Clin Pharmacokinet· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis